The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
The post discusses using finasteride, minoxidil, ketoconazole, and a dermaroller for hair loss, along with spearmint capsules, pueraria mirifica, saw palmetto, biotin, and vitamins. The user is also considering microdosing finasteride with trans treatment and mentions the potential of herbal enemas and hair systems.